生物林斯洗脱生物基质支架与双疗法西罗莫司洗脱支架在PCI中的比较:SORT OUT XI随机试验
SORT OUT XI试验在丹麦西部三个心脏中心纳入3136例行PCI的全患者人群,1:1随机比较生物林斯A9洗脱Biomatrix Alpha支架(BES)与双疗法西罗莫司洗脱Combo支架(DTS)。1年靶病变失败(TLF)在BES组为4.2%、DTS组为5.2%,BES非劣效于DTS(非劣效P=0.00002),但BES组明确支架血栓风险显著增加(1.3% vs 0.6%,P=0.034)。
要点
- BES在1年TLF方面非劣效于DTS,风险差异-1.07%(单侧90%CI上限0.21%)。
- BES组明确支架血栓发生率显著高于DTS组(1.3% vs 0.6%,P=0.034)。
- 心源性死亡BES组1.1%、DTS组1.9%,靶病变心肌梗死两组分别为2.3%和2.1%。
核心结论
- BES在1年TLF主要终点上非劣效于DTS。
- BES与明确支架血栓风险显著增加相关。
研究设计与样本
- 多中心(丹麦Aalborg、Aarhus、Odense)随机、非劣效性试验,非劣效界值2.1%。
- 2019年8月14日至2023年3月19日纳入3136例全患者人群,1:1随机至BES组(n=1566,1891处病变)或DTS组(n=1570,1878处病变)。
- 主要复合终点为1年TLF,包括心源性死亡、靶病变心肌梗死或靶病变血运重建,按意向性治疗分析。
主要发现
- 1年TLF:BES组65例(4.2%),DTS组82例(5.2%);风险差异-1.07%(单侧90%CI上限0.21%),非劣效P=0.00002;发生率比0.79(95%CI 0.57-1.09;P=0.15)。
- 心源性死亡:BES组18例(1.1%),DTS组30例(1.9%);发生率比0.60(95%CI 0.33-1.07;P=0.08)。
- 靶病变心肌梗死:BES组36例(2.3%),DTS组33例(2.1%);发生率比1.09(95%CI 0.68-1.75;P=0.73)。
- 明确支架血栓:BES组21例(1.3%),DTS组9例(0.6%);发生率比2.33(95%CI 1.07-5.11;P=0.034)。
临床怎么用
- BES可作为PCI中非劣效于DTS的支架选择,但需警惕支架血栓风险增加。
- 临床决策时应权衡BES的TLF非劣效性与明确支架血栓风险升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Percutaneous coronary intervention (PCI) with new-generation drug-eluting stents (DES) is still associated with risk of target lesion failure (TLF). The biolimus A9-eluting Biomatrix Alpha stent (BES), with biodegradable polymer and thin struts, has not been compared head-to-head with another contemporary DES. OBJECTIVES: This study compared 1-year TLF in BES vs dual therapy sirolimus-eluting Combo stent (DTS) in an all-comer population undergoing PCI. METHODS: The trial was conducted in the 3 Western Danish Heart centers (Aalborg, Aarhus, and Odense). The primary composite endpoint was 1-year TLF defined as a composite of cardiac death, target lesion myocardial infarction, or target lesion revascularization. The trial was designed as a noninferiority trial with a noninferiority margin of 2.1%. Data were analyzed by intention-to-treat. RESULTS: From August 14, 2019, to March 19, 2023, 3,136 patients were randomized 1:1 to BES (n = 1,566; 1,891 lesions) vs DTS (n = 1,570; 1,878 lesions). In the intention-to-treat analysis, TLF at 1-year follow-up occurred in 65 patients (4.2%) in the BES group and 82 patients (5.2%) in the DTS group: risk difference: -1.07% (upper limit of 1-sided 90% CI: 0.21%), (P for noninferiority = 0.00002); incidence rate ratio: 0.79 (95% CI: 0.57-1.09; P = 0.15). Cardiac death occurred in 18 patients (1.1%) in the BES group and 30 (1.9%) in the DTS group: incidence rate ratio: 0.60 (95% CI: 0.33-1.07; P = 0.08). Target lesion myocardial infarction occurred in 36 (2.3%) in the BES group and 33 (2.1%) in the DTS group: incidence rate ratio: 1.09 (95% CI: 0.68-1.75; P = 0.73). Definite stent thrombosis occurred in 21 patients (1.3%) in the BES group and 9 (0.6%) in the DTS group: incidence rate ratio: 2.33 (95% CI: 1.07-5.11; P = 0.034). CONCLUSIONS: BES was noninferior to DTS at 1-year follow-up regarding the primary endpoint of TLF. However, BES was associated with significantly increased risk of definite stent thrombosis. (Combo Stent Versus Biomatrix Alpha Stent [SORT OUT XI] NCT03952273).
引用
- Eftekhari A, Jensen LO, Veien K, et al. Biolimus-Eluting Biomatrix Stent vs a Dual-Therapy Sirolimus-Eluting Stent in PCI: The SORT OUT XI Randomized Trial. J Am Coll Cardiol. 2025. PMID: 40406942. doi:10.1016/j.jacc.2025.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。